

### Amendments to the Claims

The following listing of claims replaces all listings of claims previously presented in this application.

Claims 1-53 (Canceled)

54. (New) A preparation comprising a predominant amount of a monopolymer/protein conjugate prepared from a hematopoietic protein having one or more available epsilon amino reactive groups,

wherein the monopolymer/protein conjugate has a polyethylene glycopolymer moiety located at the N-terminus but not on an epsilon amino group, and the polyethylene glycol polymer moiety is conjugated via an alpha amino group and,

wherein the monopolymer/protein conjugate has a prolonged *in vivo* biological activity relative to the non-conjugated hematopoietic protein.

55. (New) The preparation of claim 54 wherein the preparation comprises greater than 80% monopolymer/protein conjugate.

56. (New) The preparation of claim 54 wherein the preparation comprises at least 90% monopolymer/protein conjugate.

57. (New) The preparation of claim 54 wherein the preparation comprises greater than 95% monopolymer/protein conjugate.

58. (New) The preparation of claim 54 wherein the preparation comprises at least 99% monopolymer/protein conjugate.

59. (New) A preparation of a monopegylated hematopoietic protein prepared from a hematopoietic protein having one or more available epsilon amino reactive groups,

wherein a polyethylene glycol polymer moiety is conjugated predominantly at the N-terminus of the hematopoietic protein and is conjugated via an alpha amino group and

wherein the monopegylated hematopoietic protein has a prolonged *in vivo* biological activity relative to the non-conjugated hematopoietic protein.

60. (New) The hematopoietic protein preparation of claim 54 or 59 wherein the polyethylene glycol has a molecular weight of between about 2 kDa and about 100 kDa.

61. (New) The hematopoietic protein preparation of claim 60 wherein the polyethylene glycol has a molecular weight of about 6 kDa.

62. (New) The hematopoietic protein preparation of claim 60 wherein the polyethylene glycol has a molecular weight of about 12 kDa.

63. (New) The hematopoietic protein preparation of claim 60 wherein the polyethylene glycol has a molecular weight of about 20 kDa.

64. (New) The hematopoietic protein preparation of claim 60 wherein the polyethylene glycol has a molecular weight of about 25 kDa.

65. (New) A pharmaceutical composition comprising (a) the preparation of claim 54, 55, 56, 57, 58, 59, 60, 61, 62, 63 or 64 and (b) a pharmaceutically acceptable diluent, carrier or adjuvant.